Abstract
Align Technology will report first-quarter 2026 results on April 29, 2026 Post Market; this preview consolidates consensus forecasts for revenue, margins, net income, and adjusted EPS, reviews last quarter’s performance, and highlights the core drivers and analyst expectations shaping the print.
Market Forecast
Consensus expects Align Technology’s first-quarter 2026 revenue to reach 1.02 billion US dollars, up 4.81% year over year, with adjusted EPS forecast at 2.28, up 14.87% year over year, and estimated EBIT of 194.91 million US dollars, up 9.18% year over year. Forecasts for gross margin and net margin have not been issued; expectations center on stable operating execution against a softer seasonal backdrop versus the prior quarter’s peak.
Highlights for the core business point to steady case demand and sustained traction in digital workflows, supported by continued engagement from dental organizations and improving activity in selected international markets. The most promising segment remains clear aligners, which generated 838.15 million US dollars last quarter, rising approximately 5.50% year over year.
Last Quarter Review
In the most recently reported quarter, Align Technology delivered revenue of 1.05 billion US dollars (up 5.26% year over year), a gross profit margin of 72.47%, GAAP net income attributable to shareholders of 136.00 million US dollars, a net margin of 12.96%, and adjusted EPS of 3.29 (up 34.84% year over year).
Results modestly exceeded consensus on both revenue and EPS, reflecting disciplined cost control and a favorable seasonal mix of higher-margin cases into the year-end period. Main business performance was led by clear aligners at 838.15 million US dollars (about 5.50% year-over-year growth in the quarter), complemented by 209.42 million US dollars from iTero scanners and related systems and services.
Current Quarter Outlook
Core Aligner Business
The aligner segment remains the center of attention this quarter, with investors watching unit volumes, average selling prices, and case mix as offices settle into early-year demand patterns. Based on the company’s forecast framework and market expectations, total revenue is seen growing 4.81% year over year to 1.02 billion US dollars, which implies mid–single digit expansion for the core business despite a calendar period that is typically less robust than the fourth quarter. The operating cadence suggests Align is balancing promotional discipline with case growth opportunities, particularly in geographies and channels that showed encouraging momentum exiting last year.
Mix remains crucial for gross profit sustainability. A higher proportion of teen and comprehensive cases can support pricing, while starter-case counts and adoption among general dentists underpin volume. The prior quarter’s 72.47% gross margin provides a strong baseline, and the EBIT forecast of 194.91 million US dollars points to controlled operating spending even as customer-facing investments are maintained. Intra-quarter, management emphasis on digital treatment planning and chairside efficiency is likely to remain a differentiator, helping doctor adoption and conversion as offices pursue predictable outcomes and streamlined workflows.
Regional dynamics matter for the quarterly setup. Offices across North America and key international markets are focusing on case conversion consistency, with selected improvement in Asia-Pacific seen in recent months. The cadence of shipments, training activity, and practice engagement events typically defines in-quarter revenue phasing. While the quarter lacks the seasonal tailwind embedded in the prior period, the current forecasting range indicates limited downside to unit trends, provided practice utilization levels remain intact and scheduled consultations translate into starts at a stable rate.
Most Promising Growth Engine
Clear aligners are positioned as the strongest growth engine, supported by higher engagement among teens and growing awareness in key international markets. Last quarter’s clear aligner revenue of 838.15 million US dollars and about 5.50% year-over-year growth provide a sturdy base for the current period’s forecast, with sustained traction in teen cases often translating into durable demand across the practice. In prior updates, international momentum—especially in Asia-Pacific—has been an incremental tailwind for shipments, and it remains pivotal to the growth narrative this quarter.
A critical component is the expansion of digital case planning and the ongoing enhancement of chairside tools, which can bolster both doctor confidence and patient acceptance rates. This is especially relevant for larger dental organizations and high-volume practices that value predictable outcomes and end-to-end digital integration. Continued training initiatives, refinement of clinical protocols, and broader education for general dentists should help extend the addressable opportunity within existing customer bases, improving utilization and smoothing variability in weekly case starts.
The margin implications of this growth engine are also constructive. Teen and comprehensive treatments typically support better pricing, and improved digital workflows can reduce refinements and chair time, preserving gross margin. With EBIT expected to rise 9.18% year over year to 194.91 million US dollars, the model shows resilience even if currency or seasonal effects weigh on headline revenue. The focus for this quarter is on converting the current pipeline of consults into starts while protecting pricing and avoiding aggressive promotional moves that could dilute profitability.
Stock Price Drivers This Quarter
Engagement by an activist shareholder became a fresh narrative in March, with reports on March 19, 2026 and March 20, 2026 indicating a sizable stake and a push for actions that could enhance shareholder value. This development adds a new lens to the quarter: investors may look for signals on capital deployment, operating efficiency, and portfolio priorities that could align with a value-creation roadmap. Any commentary around capital returns, cost initiatives, or structural optimization will receive heightened scrutiny in management’s discussion.
Analyst sentiment has trended more positive through February, March, and April, with multiple upgrades and constructive previews emphasizing case momentum stabilization, digital ecosystem strength, and potential for incremental improvements in operating margin. Into the print, price targets were raised by several well-known investment banks, pointing to recovering confidence in the trajectory of revenue and earnings. The market may react strongly to disclosure around case starts, ASPs, and commentary on demand conditions across dental organizations and key international markets, given their leverage to both near-term revenue and forward margin expectations.
Macro and micro variables may intersect to influence the stock around the release. Currency remains a factor for reported results, and the quarter’s typical seasonality can amplify small shifts in unit volume. On the micro side, practice activity levels, appointment pipelines, and patient financing availability can shape weekly conversion rates. Given the EBIT forecast growth of 9.18% year over year and adjusted EPS forecast growth of 14.87% year over year, management’s tone on sustainability through the rest of 2026 could be as important as the headline numbers for the near-term multiple.
Analyst Opinions
Bullish opinions substantially outweigh bearish views in the year-to-date period through April 22, 2026, with recent Buy/Overweight calls and upgrades from several major institutions outweighing a single prominent Sell. The ratio of bullish to bearish commentary is approximately 6:1. Notable positive voices include upgrades or Buy initiations from Barclays (Overweight on March 18, 2026), HSBC (Buy on February 10, 2026), and Citigroup (Buy initiation with an upgraded price framework on April 15, 2026), alongside Piper Sandler’s higher price target and maintained Overweight on April 21, 2026. Additional supportive stances came from William Blair (Buy in January 2026) and Mizuho (Buy in February 2026), both highlighting strengthening demand signals through dental organizations and improving visibility on revenue conversion.
The bullish camp centers on three pillars. First, they see the current-quarter setup as a manageable seasonality trade-off relative to the prior quarter’s strength, underpinned by mid–single digit year-over-year growth in total revenue to about 1.02 billion US dollars and improving non-GAAP profitability, reflected in the 14.87% forecast growth in adjusted EPS to 2.28. Second, the continued build-out of digital workflows and case planning is viewed as a structural advantage for adoption, where training, clinical protocol consistency, and integration with chairside systems can translate to steadier case starts. Third, several analysts point to incremental momentum among dental service organizations and larger multi-location practices, which have the operational scale to translate training and workflow improvements into higher volumes and margin-friendly case mix over time.
Barclays’ upgrade emphasized improving conviction in demand normalization against a more supportive setup for execution as the year progresses, with attention on revenue stability and the visibility of the earnings bridge. HSBC’s upgrade to Buy highlighted a better risk-reward balance at current valuations, with upside tied to steady unit progression and operating leverage as growth resumes. Citigroup’s Buy initiation outlined a constructive multiquarter framework, pointing to near-term support from mid–single digit year-over-year revenue growth and the potential for further margin progress as digital adoption deepens. Piper Sandler’s updated target and reaffirmed Overweight reflected rising confidence in execution metrics and the path for revenue and EBIT expansion through 2026.
William Blair reiterated a constructive stance based on what they assessed as resilient demand through dental organizations and improving signals from offices adopting more comprehensive digital treatment planning. Mizuho echoed the improving setup, expecting Align to lean on its digital ecosystem and practice support to drive consistent case conversion. Across these notes, the majority view converges on a single conclusion: the quarter’s qualitative tone on case starts, ASPs, and regional momentum—combined with the activist catalyst—could sustain sentiment provided management confirms that the revenue and earnings cadence implied by forecasts is on track.
Market-facing investors will likely focus on how the company frames its second-quarter and full-year cadence. A steady guidepost for case volumes and a reaffirmation of investment priorities around digital workflows would match the bullish narrative that near-term growth is stabilizing and medium-term earnings power is intact. Should management’s commentary align with the consensus profile—revenue up 4.81% year over year to 1.02 billion US dollars, EBIT rising 9.18% year over year to 194.91 million US dollars, and adjusted EPS up 14.87% year over year to 2.28—the upgrade cycle that accelerated in March and April could remain a supportive backdrop for the shares.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments